Recently, a new view into the molecular mechanisms of phosphate homeostasis and secondary hyperparathyroidism pathogenesis has been proposed, with Fibroblast Growth Factor 23 (FGF-23) as a novel player in the field. Enhanced serum FGF-23 levels cause a reduction in serum phosphate, together with calcitriol suppression and consequent hyperparathyroidism. In contrast, reduced serum FGF-23 levels are associated with hyperphosphatemia, higher calcitriol levels and parathyroid hormone (PTH) suppression. In addition, there are different FGF-23 actions that need investigation. In clinical practice, increased knowledge of mineral metabolism disorders alterations in chronic kidney disease (CKD) may be used to improve diagnostics and select future treatments. The discovery of FGF23 represents a novel factor in the pathogenesis of phosphate handling and secondary hyperparathyroidism in cardiovascular, bone and renal disease.

The Fibroblast Growth Factor 23: A New Player in the Field of Cardiovascular, Bone and Renal Disease / Mario, Cozzolino; Mazzaferro, Sandro. - In: CURRENT VASCULAR PHARMACOLOGY. - ISSN 1570-1611. - 8:3(2010), pp. 404-411. [10.2174/157016110791112313]

The Fibroblast Growth Factor 23: A New Player in the Field of Cardiovascular, Bone and Renal Disease

MAZZAFERRO, SANDRO
2010

Abstract

Recently, a new view into the molecular mechanisms of phosphate homeostasis and secondary hyperparathyroidism pathogenesis has been proposed, with Fibroblast Growth Factor 23 (FGF-23) as a novel player in the field. Enhanced serum FGF-23 levels cause a reduction in serum phosphate, together with calcitriol suppression and consequent hyperparathyroidism. In contrast, reduced serum FGF-23 levels are associated with hyperphosphatemia, higher calcitriol levels and parathyroid hormone (PTH) suppression. In addition, there are different FGF-23 actions that need investigation. In clinical practice, increased knowledge of mineral metabolism disorders alterations in chronic kidney disease (CKD) may be used to improve diagnostics and select future treatments. The discovery of FGF23 represents a novel factor in the pathogenesis of phosphate handling and secondary hyperparathyroidism in cardiovascular, bone and renal disease.
2010
chronic kidney disease; fgf-23; klotho; phosphatonins; secondary hyperparathyroidism; vascular calcification
01 Pubblicazione su rivista::01a Articolo in rivista
The Fibroblast Growth Factor 23: A New Player in the Field of Cardiovascular, Bone and Renal Disease / Mario, Cozzolino; Mazzaferro, Sandro. - In: CURRENT VASCULAR PHARMACOLOGY. - ISSN 1570-1611. - 8:3(2010), pp. 404-411. [10.2174/157016110791112313]
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/143756
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 11
  • Scopus 27
  • ???jsp.display-item.citation.isi??? 26
social impact